Table 2.

Ongoing trials examining IGF-1 as a potential treatment in several childhood-onset neurodevelopmental disorders.

References	Disorder	Treatment	Dose	Sample size	Study type	Treatment duration	Findings	Company (if applicable)
NCT01777542	RTT	rhIGF-1	Unknown	In progress	Phase II Trial	10 months	In progress	–
NCT02715115	RTT	NNZ-2566	Various	In progress	Phase II Trial	11 weeks (avg.)	In progress	Neuren Pharmaceuticals Ltd.
NCT01970345	ASD	rhIGF-1	0.04 mg/kg bd to a maximum of 0.12 mg/kg bd	In progress	Phase II Trial	12 weeks	In progress	–

RTT, Rett Syndrome; FXS, Fragile X Syndrome; PMDS, Phelan McDermid Syndrome; ASD, Autism Spectrum Disorder.